Cancer Conversations™: PARP Inhibitors in Ovarian Cancer

Get up to date on the most recent developments in leveraging PARP inhibitors to optimally manage ovarian cancer with slides and an on-demand webcast capturing a dynamic Cancer Conversations webinar featuring expert discussion on key areas of consensus and controversy involving the latest data.

Share

Program Content

Activities

PARPi in Ovarian Cancer
Cancer Conversations™: PARP Inhibitors in Ovarian Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 18, 2021

Expires: October 17, 2022

<i>EP</i>: PARPi in OC
ExpressPoints
Cancer Conversations™: PARP Inhibitors in Ovarian Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 28, 2021

Expires: October 27, 2022

Activities

PARPi in Ovarian Cancer
Cancer Conversations
PARP Inhibitors in Ovarian Cancer
Case Challenge
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: November 05, 2021

Expires: November 04, 2022

Faculty

cover img faculity

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

cover img faculity

Kathleen N. Moore, MD, MS

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Associate Director Clinical Research
Stephenson Cancer Center at OU Health
Oklahoma City, Oklahoma

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.